Formulation development and evaluation of medroxyprogesterone acetate injectable suspension

  • M. Sunitha Reddy Department of pharmaceutics, Centre of pharmaceutical sciences, IST, JNTU, Hyderabad, India
  • B. Samatha Department of pharmaceutics, Centre of pharmaceutical sciences, IST, JNTU, Hyderabad, India

Abstract

The aim of the present work is to develop sustained release parenteral drug delivery system of contraceptive drug i., e medroxyprogesterone acetate. The formulation was prepared by sterile combining of API and excipient powders by rapid stirring method. Different excipients used in the formulation are PEG 3350, Poloxamer -188, Polysorbate-80, Benzyl alcohol and Sodium chloride. The prepared parenteral suspension was evaluated for all official parameters like sedimentation volume, measurement of zeta potential, pH, viscosity, osmolality, dissolution, assay, particle size determination, and stability studies. The dissolution profile was found to be more when compared with the innovator formulation. Stability studies were also conducted at 25ºC / 60% RH and 40ºC / 75% RH conditions up to 3M.All the parameters evaluated are within the specified limits.


Keywords: Medroxy progesterone acetate, PEG 3350, Poloxamer-188, injectable suspension.

Downloads

Download data is not yet available.

Author Biographies

M. Sunitha Reddy, Department of pharmaceutics, Centre of pharmaceutical sciences, IST, JNTU, Hyderabad, India

Department of pharmaceutics, Centre of pharmaceutical sciences, IST, JNTU, Hyderabad, India

B. Samatha, Department of pharmaceutics, Centre of pharmaceutical sciences, IST, JNTU, Hyderabad, India

Department of pharmaceutics, Centre of pharmaceutical sciences, IST, JNTU, Hyderabad, India

References

1. Patel RM, Parenteral suspension: an overview, International Journal of current Pharmaceutical Research, 2010; 2(3):5-13
2. Aungst B. J, Intestinal permeation enhancers, Journal of Pharmaceutical Sciences, 2000; 89(4):428-442.
3. Lawrence M. J, Microemulsion-based media as novel drug delivery systems, Advanced Drug Delivery Reviews, 2000; 45(1): 89-121.
4. Patel CA, Keraliya R, A review: Parenteral depot drug delivery system, Journal of Drug Delivery Research, 2014; 3(1):1-10.
5. Parrott E L, Pharmaceutical technology: fundamental pharmaceutics, Burgness Publishing Company; 1970.
6. Cundy T, Farqubar CM, Cornish J, Reid IR, Short-term effects of high dose oral medroxy progesterone acetate on bone density in premenopausal women, Journal of Clinical Endocrinology and Metabolism, 1995; 81(3):1014-1017.
7. Chaurasia G, A review on pharmaceutical preformulation studies in formulation and development of new drug molecules, International Journal of Pharmaceutical Sciences and Research, 2016; 7(6):2313-2320.
8. Alam. A, Alka Ahuja, Sanjula Baboota, S. K. Gidwani, J. Ali, Formulation and evaluation of pharmaceutically equivalent parenteral depot suspension of methyl prednisolone acetate, Indian Journal of Pharmaceutical Sciences, 2009; 71(1):30-34.
9. William P. Forrest, Kevin G. Reuter, Vivek Shah, Irina Kazakevich, Michael Heslinga, Siddhi Dudhat, Sanjaykumar Patel, Claudia Neri, Yun Mao, USP Apparatus 4: A Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds, AAPS PharmSciTech, 2017; 19(1):413-424.
10. Raymond C.R., Paul J.S., Marian E.Q. Handbook of Pharmaceutical excipients. Sixth edition. U.K.
Crossmark
Statistics
1370 Views | 961 Downloads
How to Cite
1.
Sunitha Reddy M, Samatha B. Formulation development and evaluation of medroxyprogesterone acetate injectable suspension. JDDT [Internet]. 15Dec.2018 [cited 29Mar.2024];8(6-s):298-03. Available from: https://www.jddtonline.info/index.php/jddt/article/view/2146